Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Offering improved detection for breast cancer in women with dense breasts as well as enhanced diagnosis of invasive lobular cancer, the AI-powered ProFound Detection Version 4.0 software for digital breast tomosynthesis (DBT) has garnered 510(k) clearance from the Food and Drug Administration (FDA).
ProFound Detection Version 4.0 provides a 50 percent improvement for diagnosing breast cancer in women with dense breasts in comparison to the previous version of the software, according to iCAD, the manufacturer of ProFound Detection Version 4.0.
The newly FDA-cleared ProFound Detection Version 4.0 software leverages artificial intelligence (AI) to provide enhanced detection of breast cancer in women with dense breasts as well as invasive lobular cancer on digital breast tomosynthesis (DBT) in comparison to a previous version of the AI software. (Image courtesty of iCAD.)
In contrast to the third version of the software, iCAD said ProFound Detection Version 4.0 also offers a 60 percent improvement in diagnosis of invasive lobular cancer, a 38 percent improvement in detecting cancer smaller than 1 cm and a 21 percent improvement in identifying invasive breast cancer.
“ProFound Detection Version 4.0 will dramatically improve breast cancer detection,” noted Chirag Parghi, M.D., M.B.A., the chief medical officer at Solis Mammography. “The newest version’s ability to detect subtle invasive cancers, especially within dense breast tissue, addresses one of the biggest challenges in breast imaging today.”
Noting the software’s potential for reducing false positives, iCAD said ProFound Detection Version 4.0 offers a 20 percent reduction in marks related to vascular calcification and a 51 percent reduction in marks related to non-vascular calcification. The software, which will be showcased at the upcoming Radiological Society of North America (RSNA) 2024 Annual Meeting, also enables radiologists to include a prior DBT examination into the AI analysis, according to iCAD.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.